InfraReDx Launches LipiScan To Evaluate Coronary Plaque
This article was originally published in The Gray Sheet
Executive Summary
InfraReDx is launching its catheter-based LipiScan coronary imaging system, which relies upon near-infrared spectroscopy to identify plaque most likely to cause heart attacks and death, following April 25 FDA 510(k) clearance of the device